Requirements regarding dose rate and exposure time for killing of tumour cells in beta particle radionuclide therapy

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 10, 2006, Pages 1185-1195

  Carlsson, Jörgen ^a   Eriksson, Veronika ^a   Stenerlöw, Bo ^a   Lundqvist, Hans ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Low dose rate; Nuclear medicine; Radiation effects; Radionuclide; Tumour therapy

Indexed keywords

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL KILLING; COLON CARCINOMA; CONTROLLED STUDY; ELECTRON THERAPY; EXPERIMENTAL MODEL; GLIOMA CELL; HUMAN; HUMAN CELL; LOW ENERGY RADIATION; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION EXPOSURE; RADIOSENSITIVITY; REACTION TIME; TUMOR CELL; UTERINE CERVIX CARCINOMA;

APOPTOSIS; BETA PARTICLES; BETA RAYS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; NEOPLASMS; RADIATION DOSAGE; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY;

EID: 33749266047     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0109-3     Document Type: Article

References (58)

1. Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother 2003;52(5):281-296
2. Wiseman GA, Leigh BR, Erwin WD, Sparks RB, Podoloff DA, Schilder RJ, et al. Radiation dosimetry results from a phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm 2003;18(2):165-178
3. Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, De Jong M. Peptide receptor radionuclide therapy. Ann N Y Acad Sci 2004;1014:234-245
4. 90Y-labeled somatostatin analogs. J Nucl Med 2005;46(Suppl 1):92S-98S
5. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46(Suppl 1):62S-66S
6. Hoefnagel CA. Nuclear medicine therapy of neuroblastoma. Q J Nucl Med 1999;43(4):336-343
7. 131I-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 2002;20(8):2142-2149
8. DeNardo GL, O'Donnell RT, Kroger LA, Richman CM, Goldstein DS, Shen S, et al. Strategies for developing effective radioimmunotherapy for solid tumors. Clin Cancer Res 1999;5(10 Suppl):3219s-3223s
9. DeNardo SJ, Williams LE, Leigh BR, Wahl RL. Choosing an optimal radioimmuno-therapy dose for clinical response. Cancer 2002;94(4 Suppl):1275-1286
10. Carlsson J, Forssell Aronsson E, Hietala SO, Stigbrand T, Tennvall J. Tumour therapy with radionuclides: assessment of progress and problems. Radiother Oncol 2003;66(2):107-117
11. Larson SM, Krenning EP. A pragmatic perspective on molecular targeted radionuclide therapy. J Nucl Med 2005;46(Suppl 1):1S-3S
12. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 2005;46(Suppl 1):115S-127S
13. 90Y-labeled somatostatin analogs. J Nucl Med 2005;46(Suppl 1):13S-17S
14. Steel GG. Basic clinical radiobiology. London: Arnold Publisher and Hodder Headline Group; 1997
15. Hall EJ. Radiobiology for the radiologist, Chap. 5. Philadelphia: Lippincott Williams & Wilkins; 2000
16. Dillehay LE, Williams JR. Radiobiology of dose-rate patterns achievable in radioimmunoglobulin therapy. Front Radiat Ther Oncol 1990;24:96-103, discussion 121-122
17. Dale RG. Dose-rate effects in targeted radiotherapy. Phys Med Biol 1996;41(10):1871-1884
18. Murtha AD. Radiobiology of low-dose-rate radiation relevant to radioimmunotherapy. Cancer Biother Radiopharm 2000;15(1):7-14
19. Hernandez MC, Knox SJ. Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2004;59(5):1274-1287
20. Hall EJ. Radiation dose-rate: a factor of importance in radiobiology and radiotherapy. Br J Radiol 1972;45(530):81-97
21. Bedford JS, Mitchell JB. Dose-rate effects in synchronous mammalian cells in culture. Radiat Res 1973;54(2):316-327
22. Mitchell JB, Bedford JS, Bailey SM. Dose-rate effects in mammalian cells in culture III. Comparison of cell killing and cell proliferation during continuous irradiation for six different cell lines. Radiat Res 1979;79(3):537-551
23. Dillehay LE. A model of cell killing by low-dose-rate radiation including repair of sublethal damage, G2 block, and cell division. Radiat Res 1990;124(2):201-207
24. Wong JY, Williams LE, Demidecki AJ, Wessels BW, Yan XW. Radiobiologic studies comparing yttrium-90 irradiation and external beam irradiation in vitro. Int J Radiat Oncol Biol Phys 1991;20(4):715-722
25. 131I labelled ligands or antibodies. Int J Radiat Oncol Biol Phys 2000;46(4):1025-1036
26. Howell RW, Neti PV. Modeling multicellular response to nonuniform distributions of radioactivity: differences in cellular response to self-dose and cross-dose. Radiat Res 2005;163(2):216-221
27. Howell RW, Goddu SM, Rao DV. Design and performance characteristics of an experimental cesium-137 irradiator to simulate internal radionuclide dose rate patterns. J Nucl Med 1997;38(5):727-731
28. Joiner MC, Marples B, Lambin P, Short SC, Turesson I. Low-dose hypersensitivity: current status and possible mechanisms. Int J Radiat Oncol Biol Phys 2001;49(2):379-389
29. 60Co gamma rays on human tumor cells in vitro. Radiat Res 2002;158(3):311-318
30. Prise KM, Folkard M, Michael BD. A review of the bystander effect and its implications for low-dose exposure. Radiat Prot Dosimetry 2003;104(4):347-355
31. Hall EJ. The bystander effect. Health Phys 2003;85(1):31-35
32. Mothersill C, Seymour CB. Radiation-induced bystander effects - implications for cancer. Nat Rev Cancer 2004;4(2):158-164
33. Mirzaie-Joniani H, Eriksson D, Johansson A, Lofroth PO, Johansson L, Ahlstrom KR, et al. Apoptosis in HeLa Hep2 cells is induced by low-dose, low-dose-rate radiation. Radiat Res 2002;158(5):634-640
34. Mirzaie-Joniani H, Eriksson D, Sheikholvaezin A, Johansson A, Lofroth PO, Johansson L, Stigbrand T. Apoptosis induced by low-dose and low-dose-rate radiation. Cancer 2002;94(4 Suppl):1210-1214
35. Carlsson J, Hakansson E, Eriksson V, Grawe J, Wester K, Grusell E, et al. Early effects of low dose-rate radiation on cultured tumor cells. Cancer Biother Radiopharm 2003;18(4):663-670
36. Nilsson B, Montelius A. Fluence perturbation in photon beams under nonequilibrium conditions. Med Phys 1986;13(2):191-195
37. Wikman M, Steffen AC, Gunneriusson E, Tolmachev V, Adams GP, Carlsson J, et al. Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng Des Sel 2004;17(5):455-462
38. Steffen AC, Wikman M, Tolmachev V, Adams GP, Nilsson FY, Stahl S, et al. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Biother Radiopharm 2005;20(3):239-248
39. Sundberg AL, Almqvist Y, Orlova A, Blomquist E, Jensen HJ, Gedda L, et al. Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF. Eur J Nucl Med Mol Imaging 2003;30(10):1348-1356
40. Nordberg E, Steffen AC, Persson M, Sundberg AL, Carlsson J, Glimelius B. Cellular uptake of radioiodine delivered by trastuzumab can be modified by the addition of epidermal growth factor. Eur J Nucl Med Mol Imaging 2005;32(7):771-777
41. Nister M, Libermann TA, Betsholtz C, Pettersson M, Claesson-Welsh L, Heldin CH, et al. Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. Cancer Res 1988;48(14):3910-3918
42. Marin LA, Smith CE, Langston MY, Quashie D, Dillehay LE. Response of glioblastoma cell lines to low dose rate irradiation. Int J Radiat Oncol Biol Phys 1991;21(2):397-402
43. Zalutsky MR. Current status of therapy of solid tumors: brain tumor therapy. J Nucl Med 2005;46(Suppl 1):151S-156S
44. 131I-labelled E4 antibodies on cells at different depth in DU 145 spheroids. Int J Cancer 1995;63(3):387-394
45. Sundberg AL, Blomquist E, Carlsson J, Steffen AC, Gedda L. Cellular retention of radioactivity and increased radiation dose. Model experiments with EGF-dextran. Nucl Med Biol 2003;30(3):303-315
46. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995;36(10):1902-1909
47. Nilsson S, Carlsson J, Larsson B, Ponten J. Survival of irradiated glia and glioma cells studied with a new cloning technique. Int J Radiat Biol Relat Stud Phys Chem Med 1980;37(3):267-279
48. Skarsgard LD, Skwarchuk MW, Wouters BG, Durand RE. Substructure in the radiation survival response at low dose in cells of human tumor cell lines. Radiat Res 1996;146(4):388-398
49. Short SC, Mitchell SA, Boulton P, Woodcock M, Joiner MC. The response of human glioma cell lines to low-dose radiation exposure. Int J Radiat Biol 1999;75(11):1341-1348
50. Fertil B, Malaise EP. Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy. Int J Radiat Oncol Biol Phys 1981;7(5):621-629
51. Deacon J, Peckham MJ, Steel GG. The radioresponsiveness of human tumours and the initial slope of the cell survival curve. Radiother Oncol 1984;2(4):317-323
52. Frykholm G, Glimelius B, Richter S, Carlsson J. Heterogeneity in antigenic expression and radiosensitivity in human colon carcinoma cell lines. In Vitro Cell Dev Biol 1991;27A(12):900-906
53. Warenius HM, Browning PG, Britten RA, Peacock JA, Rapp UR. C-raf-1 proto-oncogene expression relates to radiosensitivity rather than radioresistance. Eur J Cancer 1994;30A(3):369-375
54. Wouters BG, Sy AM, Skarsgard LD. Low-dose hypersensitivity and increased radioresistance in a panel of human tumor cell lines with different radiosensitivity. Radiat Res 1996;146(4):399-413
55. Deschavanne PJ, Fertil B. A review of human cell radiosensitivity in vitro. Int J Radiat Oncol Biol Phys 1996;34(1):251-266
56. Chapman JD. Single-hit mechanism of tumour cell killing by radiation. Int J Radiat Biol 2003;79(2):71-81
57. 131I versus high-dose-rate external-beam irradiation in the rat pancreatic tumor cell line CA20948. Cancer Biother Radiopharm 2004;19(3):285-292
58. Collis SJ, Schwaninger JM, Ntambi AJ, Keller TW, Nelson WG, Dillehay LE, et al. Evasion of early cellular response mechanisms following low level radiation-induced DNA damage. J Biol Chem 2004;279(48):49624-49632